U.K. erectile dysfunction market is expected to reach USD 451.63 million by 2031, from USD 260.49 million in 2023 growing at the CAGR of 7.2% in the forecast period of 2024 to 2031.
Market Segmentation
U.K. Erectile Dysfunction Market, By Product Type (Drugs and Devices), Type (Secondary Erectile Dysfunction and Primary Erectile Dysfunction), Age Group (Less than 40, 40-60 and 60 - Above), End User (Hospital, Specialty Clinics, Home Healthcare, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tenders, Retail Pharmacy, Online Pharmacy, Hospital Pharmacy and Others) - Industry Trends and Forecast to 2031
Overview of U.K. Erectile Dysfunction Market Dynamics
- Driver
- Rising prevalence of chronic diseases
- Restraint
- Regulatory constraints for approval
- Opportunity
- Availability of prescription medication and its generic version
Market Players
Some of the key market players for U.K. erectile dysfunction market are:
- Lupin
- Teva Pharmaceutical Industries Ltd.
- Augusta Medical Systems
- Boston Scientific Corporation
- Coloplast Corp
- Rigicon, Inc.
- Pfizer Inc.
- Bayer AG
- Eli Lily and Company
- Viatris Inc.
- ZSI, Zephyr Surgical Implants
TABLE OF CONTENTS
1 INTRODUCTION 11
- 1.1 OBJECTIVES OF THE STUDY 11
- 1.2 MARKET DEFINITION 11
- 1.3 OVERVIEW OF U.K. ERECTILE DYSFUNCTION MARKET 11
- 1.4 CURRENCY AND PRICING 12
- 1.5 LIMITATIONS 12
- 1.6 MARKETS COVERED 13
2 MARKET SEGMENTATION 15
- 2.1 MARKETS COVERED 15
- 2.2 GEOGRAPHICAL SCOPE 16
- 2.3 YEARS CONSIDERED FOR THE STUDY 16
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 17
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 20
- 2.6 MULTIVARIATE MODELLING 21
- 2.7 MARKET END USER COVERAGE GRID 22
- 2.8 PRODUCT LIFELINE CURVE 23
- 2.9 DBMR MARKET POSITION GRID 24
- 2.10 VENDOR SHARE ANALYSIS 25
- 2.11 SECONDARY SOURCES 26
- 2.12 ASSUMPTIONS 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 29
- 4.1 PESTEL ANALYSIS 30
- 4.2 PORTER'S FIVE FORCES MODEL 31
- 4.3 VENDOR SHARE ANALYSIS 32
- 4.4 BRAND ANALYSIS 33
- 4.4.1 LEADING BRANDS 33
- 4.4.2 BRAND POSITIONING 33
- 4.4.3 MARKET PENETRATION 34
- 4.4.4 COMPETITIVE ANALYSIS 35
- 4.5 CONSUMER INSIGHTS 36
- 4.5.1 DEMOGRAPHIC INSIGHTS 36
- 4.5.2 PSYCHOGRAPHIC PROFILE 36
- 4.5.3 CONSUMER PREFERENCES 37
- 4.5.4 PURCHASING BEHAVIOUR 37
- 4.5.5 FACTORS INFLUENCING BUYING DECISION 37
- 4.6 PERFORMANCE ANALYSIS 39
- 4.7 RETAIL ANALYSIS 41
5 MARKET OVERVIEW 44
- 5.1 DRIVERS 46
- 5.1.1 RISING PREVALENCE OF CHRONIC DISEASES 46
- 5.1.2 RISING ADOPTION OF SEDENTARY LIFESTYLE AND ASSOCIATED STRESS 46
- 5.1.3 RISING PRODUCT LAUNCHES BY MAJOR MARKET PLAYERS 47
- 5.1.4 RISING PATIENT AWARENESS REGARDING THE CONDITION AND MEDICATION 47
- 5.2 RESTRAINTS 48
- 5.2.1 REGULATORY CONSTRAINTS FOR APPROVAL 48
- 5.2.2 HIGH COST OF ERECTILE DYSFUNCTION TREATMENT 48
- 5.3 OPPORTUNITIES 49
- 5.3.1 AVAILABILITY OF PRESCRIPTION MEDICATION AND ITS GENERIC VERSION 49
- 5.3.2 RISING TECHNOLOGICAL ADVANCEMENTS 49
- 5.3.3 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 50
- 5.4 CHALLENGES 51
- 5.4.1 VARIOUS SIDE EFFECTS ASSOCIATED WITH ERECTILE DYSFUNCTION DRUGS 51
- 5.4.2 LACK OF SKILLED PROFESSIONALS 51
6 U.K. ERECTILE DYSFUNCTION MARKET, BY PRODUCT TYPE 52
- 6.1 OVERVIEW 53
- 6.2 DRUGS 56
- 6.2.1 ORAL DRUGS 56
- 6.2.1.1 BRANDED 57
- 6.2.1.1.1 VIAGRA 57
- 6.2.1.1.2 CIALIS 57
- 6.2.1.1.3 LEVITRA 57
- 6.2.1.1.4 AVANAFIL 57
- 6.2.1.1.5 OTHERS 57
- 6.2.1.2 GENERIC 57
- 6.2.2 TOPICAL FORMULATION 58
- 6.2.3 PENILE INJECTIONS 58
- 6.2.3.1 PAPAVERINE 58
- 6.2.3.2 PHENTOLAMINE 58
- 6.2.3.3 PROSTAGLANDIN E1 (PGE1) 58
- 6.2.4 SUPPOSITORIES 58
- 6.3 DEVICES 59
- 6.3.1 PENIS PUMPS/VACCUM CONSTRICTION DEVICES 59
- 6.3.1.1 HAND-POWERED 59
- 6.3.1.2 BATTERY-POWERED PUMP 59
- 6.3.2 PENILE IMPLANTS 60
- 6.3.2.1 SEMIRIGID/MALLEABLE 60
- 6.3.2.2 INFLATABLE 60
- 6.3.3 SHOCK WAVE THERAPY 60
7 U.K. ERECTILE DYSFUNCTION MARKET, BY TYPE 61
- 7.1 OVERVIEW 62
- 7.2 SECONDARY ERECTILE DYSFUNCTION 65
- 7.3 PRIMARY ERECTILE DYSFUNCTION 65
8 U.K. ERECTILE DYSFUNCTION MARKET, BY AGE GROUP 66
- 8.1 OVERVIEW 67
- 8.2 LESS THAN 40 70
- 8.3 40-60 70
- 8.4 60 AND ABOVE 70
9 U.K. ERECTILE DYSFUNCTION MARKET, BY END USER 71
- 9.1 OVERVIEW 72
- 9.2 HOSPITALS 75
- 9.3 SPECIALTY CLINICS 75
- 9.4 HOME HEALTHCARE 75
- 9.5 AMBULATORY SURGICAL CENTERS 75
- 9.6 OTHERS 75
10 U.K. ERECTILE DYSFUNCTION MARKET, BY DISTRIBUTION CHANNEL 76
- 10.1 OVERVIEW 77
- 10.2 DIRECT TENDERS 80
- 10.3 HOSPITAL PHARMACY 80
- 10.4 RETAIL PHARMACY 80
- 10.5 ONLINE PHARMACY 80
- 10.6 OTHERS 80
11 U.K. ERECTILE DYSFUNCTION MARKET, COMPANY LANDSCAPE 81
- 11.1 COMPANY SHARE ANALYSIS: GLOBAL 81
12 SWOT ANALYSIS 82
13 COMPANY PROFILES 83
- 13.1 PFIZER INC. 83
- 13.1.1 COMPANY SNAPSHOT 83
- 13.1.2 REVENUE ANALYSIS 83
- 13.1.3 PRODUCT PORTFOLIO 84
- 13.1.4 RECENT DEVELOPMENTS 84
- 13.2 LUPIN 85
- 13.2.1 COMPANY SNAPSHOT 85
- 13.2.2 REVENUE ANALYSIS 85
- 13.2.3 PRODUCT PORTFOLIO 86
- 13.2.4 RECENT DEVELOPMENTS 86
- 13.3 COLOPLAST CORP 87
- 13.3.1 COMPANY SNAPSHOT 87
- 13.3.2 REVENUE ANALYSIS 87
- 13.3.3 PRODUCT PORTFOLIO 88
- 13.3.4 RECENT DEVELOPMENTS 88
- 13.4 VIATRIS INC. 89
- 13.4.1 COMPANY SNAPSHOT 89
- 13.4.2 REVENUE ANALYSIS 89
- 13.4.3 PRODUCT PORTFOLIO 90
- 13.4.4 RECENT DEVELOPMENTS 90
- 13.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 91
- 13.5.1 COMPANY SNAPSHOT 91
- 13.5.2 REVENUE ANALYSIS 91
- 13.5.3 PRODUCT PORTFOLIO 92
- 13.5.4 RECENT DEVELOPMENTS 92
- 13.6 AUGUSTA MEDICAL SYSTEMS 93
- 13.6.1 COMPANY SNAPSHOT 93
- 13.6.2 PRODUCT PORTFOLIO 93
- 13.6.3 RECENT DEVELOPMENT 93
- 13.7 BAYER AG 94
- 13.7.1 COMPANY SNAPSHOT 94
- 13.7.2 REVENUE ANALYSIS 94
- 13.7.3 PRODUCT PORTFOLIO 95
- 13.7.4 RECENT DEVELOPMENTS 95
- 13.8 BOSTON SCIENTIFIC CORPORATION 96
- 13.8.1 COMPANY SNAPSHOT 96
- 13.8.2 REVENUE ANALYSIS 96
- 13.8.3 PRODUCT PORTFOLIO 97
- 13.8.4 RECENT DEVELOPMENTS 97
- 13.9 ELI LILY AND COMPANY
- 13.9.1 COMPANY SNAPSHOT 98
- 13.9.2 REVENUE ANALYSIS 98
- 13.9.3 PRODUCT PORTFOLIO 99
- 13.9.4 RECENT DEVELOPMENTS 99
- 13.10 RIGICON, INC. 100
- 13.10.1 COMPANY SNAPSHOT 100
- 13.10.2 PRODUCT PORTFOLIO 100
- 13.10.3 RECENT DEVELOPMENT 101
- 13.11 ZEPHYR SURGICAL IMPLANTS. 102
- 13.11.1 COMPANY SNAPSHOT 102
- 13.11.2 PRODUCT PORTFOLIO 102
- 13.11.3 RECENT DEVELOPMENT 102
14 QUESTIONNAIRE 103
15 RELATED REPORTS 106